Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

61. Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist’s Perspective Full Text available with Trip Pro

Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist’s Perspective 29607297 2019 01 28 2450-131X 6 1 2018 Mar Journal of translational internal medicine J Transl Int Med Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective. 6-10 10.2478/jtim-2018-0002 Riva Nicoletta N Department of Pathology, University of Malta, Msida, Malta. Ageno Walter W Department of Medicine and Surgery, University

2018 Journal of translational internal medicine

62. VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites Full Text available with Trip Pro

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites Vitamin K reduction is catalyzed by 2 enzymes in vitro: the vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) and its isozyme VKORC1-like1 (VKORC1L1). In vivo, VKORC1 reduces vitamin K to sustain γ-carboxylation of vitamin K-dependent proteins, including coagulation factors. Inhibition of VKORC1 by oral anticoagulants (OACs) is clinically used in therapy and in prevention

2018 Blood advances

63. Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome Full Text available with Trip Pro

Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome We report 2 cases of apixaban use as prophylaxis against thromboembolism in the nephrotic syndrome (NS), and review the existing literature on direct-acting oral anticoagulant (DOAC) use in this scenario. Our cases appear to be the first reported use of apixaban as prophylaxis against thromboembolism in NS. We report our systematic review of the existing literature on direct-acting oral (...) anticoagulant (DOAC) use in NS, and discuss theoretical issues relevant to their therapeutic use in this clinical scenario. We searched electronic databases such as OVID, EMBASE, PubMed, and CENTRAL, DARE. The search to identify studies and the application of inclusion and exclusion criteria was performed in duplicate independently. We identified 1 pilot randomized study, 3 case reports, and 3 conference proceedings abstracts relating to DOAC use in NS. These reports all pertain to the treatment

2018 Kidney international reports

64. The Significance of Drug—Drug and Drug—Food Interactions of Oral Anticoagulation Full Text available with Trip Pro

The Significance of Drug—Drug and Drug—Food Interactions of Oral Anticoagulation Vitamin K antagonists (VKAs) such as warfarin are the most commonly prescribed oral anticoagulants worldwide. However, factors affecting the pharmacokinetics of VKAs, such as food and drugs, can cause deviations from their narrow therapeutic window, increasing the bleeding or thrombosis risk and complicating their long-term use. The use of direct oral anticoagulants (DOACs) offers a safer and more convenient

2018 Arrhythmia & electrophysiology review

65. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia Full Text available with Trip Pro

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01

2018 Blood advances

66. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. Full Text available with Trip Pro

Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. To assess the association between anticoagulation, ischaemic stroke, gastrointestinal and cerebral haemorrhage, and all cause mortality in older people with atrial fibrillation and chronic kidney disease.Propensity matched, population based, retrospective cohort analysis from January 2006 through (...) anticoagulation in the preceding 120 days were excluded, as were patients requiring dialysis and recipients of renal transplants.Receipt of an anticoagulant prescription within 60 days of atrial fibrillation diagnosis.Ischaemic stroke, cerebral or gastrointestinal haemorrhage, and all cause mortality.6977 patients with chronic kidney disease and newly diagnosed atrial fibrillation were identified, of whom 2434 were on anticoagulants within 60 days of diagnosis and 4543 were not. 2434 pairs were matched using

2018 BMJ

67. The safety of regional citrate anticoagulation in renal replacement therapy Full Text available with Trip Pro

The safety of regional citrate anticoagulation in renal replacement therapy 29456612 2018 11 13 1751-1437 19 1 2018 Feb Journal of the Intensive Care Society J Intensive Care Soc The safety of regional citrate anticoagulation in renal replacement therapy. 86 10.1177/1751143717735749 Hill Simon S Royal Surrey County Hospital, Guildford, UK. Creighton Elaine E Royal Surrey County Hospital, Guildford, UK. Walter Edward E Royal Surrey County Hospital, Guildford, UK. eng Journal Article 2018 02 05

2018 Journal of the Intensive Care Society

68. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation Full Text available with Trip Pro

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation Randomized clinical trials comparing direct oral anticoagulants (DOACs) to warfarin in cancer patients have not been performed. We evaluated the effectiveness and associated risk of DOACs vs warfarin, as well as comparisons of DOACs, in a large population of cancer patients with nonvalvular atrial fibrillation (AF). Using the MarketScan databases, we identified 16 096 AF patients (...) (mean age, 74 years) initiating oral anticoagulant and being actively treated for cancer between 2010 and 2014. Anticoagulant users were matched by age, sex, enrollment date, and drug initiation date. Study end points were identified with diagnostic codes and included ischemic stroke, severe bleeding, other bleeding, and venous thromboembolism (VTE). Cox regression was used to estimate associations of anticoagulants with study end points. Compared with warfarin, rates of bleeding (hazard ratio [95

2018 Blood advances

69. Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. Full Text available with Trip Pro

Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. Although non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH).To assess the association between preceding oral anticoagulant use (warfarin, NOACs, and no oral anticoagulants [OACs]) and in-hospital mortality among

2018 JAMA

70. Direct oral anticoagulants or warfarin for A fib?

Direct oral anticoagulants or warfarin for A fib? Direct oral anticoagulants or warfarin for A fib? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Direct oral anticoagulants or warfarin for A fib? View/ Open Date 2017-08 Format Metadata Abstract A recent study evaluated the effectiveness of 3 direct oral (...) anticoagulants and warfarin in patients with atrial fibrillation. So which agents came out on top? PRACTICE CHANGER: Use direct oral anticoagulants instead of warfarin in patients with atrial fibrillation because they are just as effective at preventing ischemic stroke and systemic emboli as warfarin, and because apixaban and dabigatran have lower bleeding rates. Stength of recommendation: B: Based on a single, prospective, cohort study. URI Part of Citation Journal of Family Practice, 66(8) 2017: 518-520

2018 PURLS

71. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications Full Text available with Trip Pro

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Ther… | Regional Anesthesia & Pain Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage (...) or password? You are here Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Ther… Article Text Chronic and Interventional Pain: Special Article Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional

2018 American Academy of Pain Medicine

72. Less dementia with oral anticoagulation in atrial fibrillation Full Text available with Trip Pro

Less dementia with oral anticoagulation in atrial fibrillation The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect.Retrospective registry study of all patients (...) with hospital diagnosis of AF and no previous diagnosis of dementia in Sweden between 2006 and 2014. Propensity score matching, falsification endpoints, and analyses according to intention to treat as well as on-treatment principles were used. The study included 444 106 patients and over 1.5 million years at risk. Patients on anticoagulant treatment at baseline was associated with 29% lower risk of dementia than patients without anticoagulant treatment [hazard ratio (HR) 0.71, 95% confidence intervals (95

2018 EvidenceUpdates

73. Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults)

Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults) NHS England » Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults) Search Search Menu Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative (...) or absolute contraindications to anticoagulation (adults) Document first published: 9 July 2018 Page updated: 9 July 2018 Topic: , Publication type: This policy document outlines the arrangements for funding of treatment for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation. Document PDF 572 KB 28 pages

2018 NHS England

74. Venous thromboembolism — treating with the right anticoagulant and duration

Venous thromboembolism — treating with the right anticoagulant and duration '); } else { document.write(' '); } ACE | Venous thromboembolism — treating with the right anticoagulant and duration Search > > Venous thromboembolism — treating with the right anticoagulant and duration - Venous thromboembolism — treating with the right anticoagulant and duration Published on 28 May 2018 This Appropriate Care Guide (ACG) gives guidance on selecting an appropriate anticoagulant, minimum treatment (...) duration, and when to extend therapy. A supplementary guide on switching between anticoagulants is included. Download the PDF below to access the full ACG. Key Messages 1. Unless contraindicated, treat patients with warfarin or a non-vitamin K antagonist oral anticoagulant if they have proximal deep vein thrombosis or pulmonary embolism. 2. Use warfarin if creatinine clearance (measured with the Cockcroft-Gault formula) is less than 30 mL/min. 3. If patient has active cancer, use low molecular weight

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

76. Pharmacogenetic testing for patients being treated with anticoagulants

Pharmacogenetic testing for patients being treated with anticoagulants Final Pharmacogenetic testing/ oral anticoagulants: findings and decision Page 1 of 3 Health Technology Clinical Committee Findings and Decision Topic: Pharmacogenetic testing for patients being treated with oral anticoagulants Meeting date: May 18, 2018 Final adoption: July 13, 2018 Meeting materials and transcript are available on the HTA website. Number and coverage topic: 20180518B - Pharmacogenetic testing for patients (...) being treated with oral anticoagulants HTCC coverage determination: Pharmacogenetic testing for patients being treated with oral anticoagulants is not a covered benefit. HTCC reimbursement determination: Limitations of coverage: N/A Non-covered indicators: N/A Agency contact information: Agency Phone Number Labor and Industries 1-800-547-8367 Public Employees Health Plan 1-800-200-1004 Washington State Medicaid 1-800-562-3022 WA - Health Technology Assessment July 13, 2018 Final Pharmacogenetic

2018 Washington Health Care Authority

77. Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study Full Text available with Trip Pro

Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study Atrial fibrillation (AF) is associated with a high risk of thromboembolic stroke and oral anticoagulation therapy (OAT) is able to reduce the rate of ischemic events. Nevertheless, the actual benefit of prolonged OAT after successful radiofrequency catheter ablation (RFCA) is not clear yet.Scientific investigations were assumed suitable if they assessed (...) the clinical significance of the use of anticoagulation versus no anticoagulation in AF patients undergoing successful RFCA. The odds ratio (OR) with 95% confidence interval (CI) was used as the study summary measure.At meta-analysis, the rate of total thromboembolic events was not significantly different between the groups (OR 1.83, 95% CI 0.69-4.88; p = 0.221), while a lower incidence of total bleeding events in patients not treated with OAT was found (OR 6.5, 95% CI 1.93-21.86; p = 0.002).This meta

2017 Frontiers in cardiovascular medicine

78. Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants Full Text available with Trip Pro

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants Clinical factors and patient preferences are important for selecting oral anticoagulants for venous thromboembolism (VTE) and atrial fibrillation (AF). The relative association of sociodemographic factors with anticoagulant use is unknown. We evaluated a prospective cohort to compare sociodemographic variables in patients who continued on warfarin for AF or VTE to those who transitioned (...) to 1 of the direct oral anticoagulants (DOACs). Adult patients, newly started on warfarin, were enrolled through 6 anticoagulation clinics across Michigan. Of 8468 patients, 53.3% had AF, 45.6% had VTE, and 1.1% had both. Of these, 696 (8.2%) switched from warfarin to a DOAC. There were no significant differences between switchers and nonswitchers for percentage of time with a therapeutic international normalized ratio on warfarin, urban-rural residence status, or health insurance. Switchers were

2017 Blood advances

79. American Geriatrics Society Beers Criteria and Anticoagulant Use in Older Adults With Renal Impairment Full Text available with Trip Pro

American Geriatrics Society Beers Criteria and Anticoagulant Use in Older Adults With Renal Impairment 29340340 2018 11 13 2468-0249 3 1 2018 Jan Kidney international reports Kidney Int Rep American Geriatrics Society Beers Criteria and Anticoagulant Use in Older Adults With Renal Impairment. 222-223 10.1016/j.ekir.2017.11.006 Foody JoAnne J Janssen Pharmaceuticals, Inc, Titusville, New Jersey, USA. Moore Kenneth Todd KT Janssen Pharmaceuticals, Inc, Titusville, New Jersey, USA. eng Journal

2017 Kidney international reports

80. Management of Complications in Anticoagulated Patients with Atrial Fibrillation Full Text available with Trip Pro

Management of Complications in Anticoagulated Patients with Atrial Fibrillation Oral anticoagulation is mandatory for patients at high risk of thromboembolism, but the risk of bleeding should also be taken into account. Direct oral anticoagulants are now recommended for non-valvular AF as a potential alternative to warfarin. In this article we discuss methods to assess the anticoagulant effect of these agents, specific and general antidotes, and management of complications such as embolic

2017 Arrhythmia & electrophysiology review